Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 18/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 17/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3507031 | 0.90 | NR1H3 (0.46) | NR1H3NR1H2RXRACYP4F2CYP4A11 | |
| SCHEMBL3507547 | 0.90 | MEN1 (0.48) | NR1H3NR1H2MEN1KMT2ARXFP1 | |
| SCHEMBL3507588 | 0.88 | NR1H3 (0.46) | NR1H3NR1H2RXRACYP4F2CYP4A11 | |
| SCHEMBL3505406 | 0.87 | NR1H2 (0.60) | NR1H3NR1H2RXRA | |
| SCHEMBL3508932 | 0.85 | NR1H3 (0.56) | NR1H3NR1H2RXRA | |
| SCHEMBL3506261 | 0.84 | MEN1 (0.46) | NR1H3NR1H2MEN1KMT2ARXFP1 | |
| SCHEMBL4014198 | 0.83 | NR1H3 (0.47) | NR1H3NR1H2RXRACYP4F2CYP4A11 | |
| SCHEMBL3506329 | 0.82 | NR1H2 (0.60) | NR1H3NR1H2RXRA | |
| SCHEMBL3510822 | 0.81 | NR1H2 (0.60) | NR1H3NR1H2RXRA | |
| SCHEMBL3508419 | 0.80 | NR1H2 (0.57) | NR1H3NR1H2RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273816-A1 | Quinazoline Compounds | WYETH LLC | 2010-10-28 | — | — | US | claimed |
| EP-2142517-A2 | QUINAZOLINE COMPOUNDS | Wyeth (US) | 2010-01-13 | — | — | EP | claimed |
| WO-2009020683-A2 | QUINAZOLINE COMPOUNDS | WYETH (US) | 2009-02-12 | — | — | WO | claimed |
| US-20100273816-A1 | Quinazoline Compounds | WYETH LLC | 2010-10-28 | — | — | US | disclosed |
| EP-2142517-A2 | QUINAZOLINE COMPOUNDS | Wyeth (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2009020683-A2 | QUINAZOLINE COMPOUNDS | WYETH (US) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273816-A1 | Quinazoline Compounds | NR1H3, NR1H2, NR1I3 | NR1H3 1/4885NR1H2 2/4885RXRA 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.